<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03806803</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00087406</org_study_id>
    <nct_id>NCT03806803</nct_id>
  </id_info>
  <brief_title>Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection</brief_title>
  <official_title>A Multicenter Double Blind Randomized Study Comparing the Efficacy of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplantation (FMT) in the Management of Recurrent Clostridioides Difficile Infection (CDI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fecal microbiota transplantation (FMT) is a treatment that restores the balance of gut
      bacteria and is the most effective treatment for patients who suffer from recurrent
      Clostridioides difficile infection (CDI) brought on by antibiotic use. Although highly
      effective, we do not understand how FMT actually works.

      Freeze-dried or lyophilized fecal microbiota transplant (LFMT) has been shown to be
      effective. Recently, filtered fecal slurry, free of any live bacteria, has also been shown to
      cure 5 such patients. The advantage of the filtered fecal slurry is that it may be safer to
      patients as it does not contain any live bacteria. We have conducted a pilot study comparing
      LFMT to lyophilized sterile fecal filtrate (LSFF) in 9 patients, and found that the success
      rate of treatment was 80% vs 75% in these 2 groups.

      Therefore we need to perform a larger multicenter study to compare LFMT to LSFF to determine
      the success rate of curing these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective double blind randomized study will enroll 110 patients with recurrent
      Clostridium difficile infection (RCDI) in a 1:1 ratio to receive either LFMT or LSFF by
      capsules.

      Patients will receive 15 capsules at week 0 and be assessed at weeks 1, 4, 8 and 24. Blood,
      stool and urine samples will be collected. If the first treatment fails, patients will be
      given open label LFMT from the same donor. If treatment fails again, FMT will be offered in
      the form and route at the treating physician's discretion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2019</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>LFMT and LSFF appear identical. Randomization is performed by lab staff not involved in any aspect of treatment administration or care.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of RCDI</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of patients without RCDI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of RCDI</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients with sustained cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mortality directly attributable to CDI or treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
    <description>Infection directly attributable to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor Adverse Events</measure>
    <time_frame>1 week</time_frame>
    <description>Nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor Adverse Events</measure>
    <time_frame>1 week</time_frame>
    <description>Vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor Adverse Events</measure>
    <time_frame>1 week</time_frame>
    <description>Abdominal discomfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulty swallowing capsules</measure>
    <time_frame>1 week</time_frame>
    <description>Reported by patients as ranging between none, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever</measure>
    <time_frame>1 week</time_frame>
    <description>Temperature of &gt;37.8C</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Clostridia Difficile Colitis</condition>
  <condition>Clostridium Difficile Diarrhea</condition>
  <arm_group>
    <arm_group_label>LFMT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lyophilized fecal microbiota transplant capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LSFF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lyophilized sterile fecal filtrate capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lyophilized fecal microbiota transplant</intervention_name>
    <description>15 capsules</description>
    <arm_group_label>LFMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lyophilized sterile fecal filtrate</intervention_name>
    <description>15 capsules</description>
    <arm_group_label>LSFF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 3 episodes of recurrent CDI with each episode defined as 3 or more unformed
             stools in 24 hours associated with positive Clostridium difficile test, each occurring
             within 3 months of each other.

          -  CDI infection under symptomatic control with 3 or fewer unformed stools in 24 hours
             for at least 2 consecutive days prior to treatment

          -  Ability to provide informed consent

          -  Females and males must agree to effective contraception for the duration of the study

        Exclusion Criteria:

          -  Severe or fulminant colitis

          -  Chronic diarrheal illnesses such as irritable bowel syndrome or inflammatory bowel
             disease unless under control or in remission 3 months prior to enrollment.

          -  Chemotherapy or radiation therapy

          -  Oropharyngeal or significant esophageal dysphagia

          -  Ileus or small bowel obstruction

          -  Pregnant or planning to become pregnant within 3 months

          -  Breastfeeding or planning to breastfeed during the trial

          -  Active infection requiring antibiotics

          -  Life expectancy &lt;6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina Kao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dina Kao, MD</last_name>
    <phone>780 492 8307</phone>
    <email>dkao@ualberta.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina Kao, MD</last_name>
      <phone>780 492 8307</phone>
      <email>dkao@ualberta.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 1J8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrei Musaji, MD</last_name>
      <phone>250-519-7700</phone>
      <phone_ext>12939</phone_ext>
      <email>andrei.musaji@VIHA.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Calgary</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Louie, MD</last_name>
      <phone>403-944-2038</phone>
      <email>thomas.louie@albertahealthservices.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 14, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

